The discovery in 1996 [10] of a second ER subtype, known as beta (ER-β), which presented different expression profiles in normal and malignant tissues, opened the possibility that breast tumors might be even more heterogeneous than originally thought. This evidence concerns the gene ESR1 and breast neoplasm.